Revolution Medicines, Inc. (RVMD)
| Market Cap | 31.26B +400.1% |
| Revenue (ttm) | n/a |
| Net Income | -1.13B |
| EPS | -5.95 |
| Shares Out | 210.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,758,569 |
| Open | 149.48 |
| Previous Close | 149.27 |
| Day's Range | 145.52 - 151.14 |
| 52-Week Range | 34.00 - 155.70 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 135.05 (-9.14%) |
| Earnings Date | May 6, 2026 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $135.05, which is a decrease of -9.14% from the latest price.
News
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Top 2 Health Care Stocks That May Fall Off A Cliff In Q2
As of April 17, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
This Pill May Help Pancreatic Cancer Patients Live Longer
In this week's edition of InnovationRx, we look at Revolution Medicine's pancreatic cancer pill, the top self-made healthcare entrepreneurs, the latest 30 Under 30 Science & Healthcare list, and more....
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announ...
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announ...
Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough
Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer drug, raising hopes for a potential br...
Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
The late-stage clinical oncology company is focused on developing targeted therapies for patients with RAS-addicted cancers.
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial.
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemothera...
This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.
Revolution Medicines announces positive Phase 3 clinical trial results for its pancreatic cancer treatment.
Revolution Medicines' experimental cancer pill helps improve survival in late-stage study
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-sta...
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Revolution Medicines says its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer
Revolution Medicines expects to soon report results from a Phase 3 trial of its daily pill daraxonrasib for pancreatic cancer. Former Republican Sen.
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Overlooked Stock: RVMD Sells After MRK Turns Away
Revolution Medicines (RVMD) reversed a lot of its recent rally on Monday after the Wall Street Journal reported that Merck (MRK) is no longer looking to buy the biotech firm. However, as George Tsilis...
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse
Merck & Co., Inc. (NYSE: MRK) has reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ: RVMD) after the two sides disagreed on valuation.
Merck no longer in talks to buy Revolution Medicines, WSJ reports
Merck is no longer in discussions to buy cancer drug developer Revolution Medicines , the Wall Street Journal reported on Sunday.
Merck No Longer in Talks to Buy Revolution Medicines
The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.
Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
Revolution is developing drugs that target a molecular driver of cancers.
Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.
Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.
Merck in talks to buy biotech Revolution Medicines, FT reports
Merck is in talks to buy cancer drug developer Revolution Medicines , the Financial Times reported on Thursday, citing people familiar with the matter.
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previ...